Attached files

file filename
EX-99.1 - PRESS RELEASE ISSUED APRIL 10, 2014 - UROLOGIX INCurologix141405_ex99-1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (date of earliest event reported): April 10, 2014

 

 

 

Urologix, Inc.

(Exact name of Registrant as Specified in its Charter)

 

Minnesota

(State Or Other Jurisdiction Of Incorporation)

 

     
000-28414   41-1697237
(Commission File Number)   (I.R.S. Employer Identification No.)

 

     

14405 21st Avenue North

Minneapolis, MN

  55447
(Address Of Principal Executive Offices)   (Zip Code)

(763) 475-1400

Registrant’s Telephone Number, Including Area Code

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Items under Sections 1and 3 through 7 are not applicable and are therefore omitted.

 

 

ITEM 2.02    Results of Operations and Financial Condition

 

Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on April 10, 2014 disclosing material non-public information regarding the Company’s preliminary revenue for the third quarter of fiscal year 2014 ended March 31, 2014 and the Company’s preliminary cash balance as of March 31, 2014.

 

ITEM 8.01    Other Events

 

Through the press release issued on April 10, 2014 furnished with this Form 8-K as Exhibit 99.1, the Company also announced a strategic restructuring of its organizational infrastructure.

 

ITEM 9.01    Financial Statements and Exhibits

 

Exhibit Description
99.1 Press release issued by Urologix, Inc. dated April 10, 2014

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

  UROLOGIX, INC.
   
  By:  /s/ Brian J. Smrdel
    Brian J. Smrdel
Chief Financial Officer

Date: April 16, 2014